PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 11, 2019New England Journal of Medicine869 citationsOpen Access

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

View Full Paper
DSDennis J. SlamonPNPatrick NevenSCStephen Chia

Key Points

  • This research aims to evaluate the survival benefits of ribociclib plus fulvestrant compared to placebo plus fulvestrant in advanced breast cancer.
  • Participants included patients with hormone-receptor-positive, HER2-negative advanced breast cancer.
  • The study was funded by Novartis and registered under ClinicalTrials.gov number NCT02422615.
  • Ribociclib plus fulvestrant demonstrated a significant overall survival benefit compared to placebo plus fulvestrant.

Abstract

Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with hormone-receptor-positive, HER2-negative advanced breast cancer. (Funded by Novartis; MONALEESA-3 ClinicalTrials.gov number, NCT02422615.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Slamon et al. (2019) studied this question.

synapsesocial.com/papers/69d8d9b0d2f7327e70ae46b1https://doi.org/10.1056/nejmoa1911149
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer2019 · 1,040 citations
  2. 2Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-32018 · 1,140 citations
  3. 3PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro2009 · 1,422 citations
  4. 4Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint2011 · 20 citations
  5. 5MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer2017 · 1,757 citations